有投资者在互动平台向诺思格提问："公司已为国内外众多优质客户的多项临床试验项目提供符合国内 外标准的临床试验外包服务，请问公司具体合作的海外国家有哪些？" 针对上述提问，诺思格回应称："尊敬的投资者您好！公司与海外多个药企有合作，主要涉及美国、欧 洲、日本、韩国等。感谢您的关注！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 作者：公告君 ...

Core Viewpoint - The company announced a profit distribution plan for the first three quarters of 2025, proposing a cash dividend of 0.68 RMB per 10 shares to all shareholders [1] Summary by Relevant Sections - **Profit Distribution Plan** - The company will distribute a cash dividend of 0.68 RMB for every 10 shares held by shareholders [1] - **Key Dates** - The record date for the dividend is set for November 27, 2025 - The ex-dividend date is scheduled for November 28, 2025 [1]

Core Insights - Nossger (Beijing) Pharmaceutical Technology Co., Ltd. reported a revenue of 380 million yuan for the first half of 2025, reflecting a year-on-year growth of 0.18% [1] - The net profit attributable to shareholders reached 61.1161 million yuan, up 4.45% year-on-year, with a basic earnings per share of 0.64 yuan, an increase of 4.92% [1] Business Performance - The company's core business focuses on the clinical CRO sector, providing a comprehensive drug clinical research service [2] - Revenue from the clinical trial site management services (SMO) was 129 million yuan, showing a significant growth of 31.23% with a gross margin of 33.67% [2] - Clinical trial operation services (CO) generated revenue of 149 million yuan with a gross margin of 28.78% [2] - Data management and statistical analysis services (DM/ST) achieved revenue of 50.4924 million yuan, maintaining a high gross margin of 48.15% [2] - R&D investment increased by 8.59% to 30.6726 million yuan, supporting business innovation and service capability enhancement [2] Strategic Development - The company aims to expand innovative services and accelerate global business development while maintaining a focus on human health [3] - Nossger has adjusted some fundraising projects, terminating the "Data Science Center Project" to optimize resource allocation [3] - The company has established a comprehensive risk response mechanism to address industry regulatory changes, intensified market competition, and operational challenges [3]